Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
72
KYMR Quote, Financials, Valuation and Earnings
Last price:
$66.69
Seasonality move
:
7.7%
Day range:
$64.84 - $67.00
52-week range:
$19.45 - $68.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
124.87x
P/B ratio:
5.07x
Volume:
392.7K
Avg. volume:
677.1K
1-year change:
51.13%
Market cap:
$4.8B
Revenue:
$47.1M
EPS (TTM):
-$3.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KYMR
Kymera Therapeutics, Inc.
|
$23.6M | -$0.78 | 97.82% | -9.24% | $77.59 |
|
CYTK
Cytokinetics, Inc.
|
$6M | -$1.57 | -37.25% | -4.7% | $79.56 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.21% | 32.99% | $130.63 |
|
PTGX
Protagonist Therapeutics, Inc.
|
$4.1M | -$0.64 | -81.58% | -19.67% | $91.42 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -1.16% | 33.42% | $781.13 |
|
TGTX
TG Therapeutics, Inc.
|
$152M | $0.22 | 68.58% | 60.42% | $44.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KYMR
Kymera Therapeutics, Inc.
|
$66.62 | $77.59 | $4.8B | -- | $0.00 | 0% | 124.87x |
|
CYTK
Cytokinetics, Inc.
|
$65.67 | $79.56 | $8B | -- | $0.00 | 0% | 89.61x |
|
GILD
Gilead Sciences, Inc.
|
$121.22 | $130.63 | $150.4B | 18.78x | $0.79 | 2.59% | 5.24x |
|
PTGX
Protagonist Therapeutics, Inc.
|
$89.65 | $91.42 | $5.6B | 141.56x | $0.00 | 0% | 27.49x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$718.36 | $781.13 | $75.5B | 17.20x | $0.88 | 0.49% | 5.56x |
|
TGTX
TG Therapeutics, Inc.
|
$30.76 | $44.29 | $4.9B | 11.07x | $0.00 | 0% | 9.35x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KYMR
Kymera Therapeutics, Inc.
|
8.15% | 2.777 | 2.07% | 7.07x |
|
CYTK
Cytokinetics, Inc.
|
177.12% | 1.410 | 17.83% | 6.81x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
PTGX
Protagonist Therapeutics, Inc.
|
1.64% | -0.178 | 0.26% | 12.83x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
TGTX
TG Therapeutics, Inc.
|
29.47% | -1.933 | 4.53% | 2.53x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KYMR
Kymera Therapeutics, Inc.
|
$615K | -$88.7M | -30.33% | -33.29% | -3207.89% | -$27.3M |
|
CYTK
Cytokinetics, Inc.
|
-$743K | -$166.8M | -120.55% | -- | -8613.38% | -$116.9M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
PTGX
Protagonist Therapeutics, Inc.
|
$4.4M | -$46.4M | 7.03% | 7.15% | -985.17% | -$2M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
TGTX
TG Therapeutics, Inc.
|
$133.6M | $29.4M | 79.79% | 145.71% | 18.16% | -$23.2M |
Kymera Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns KYMR or CYTK?
Cytokinetics, Inc. has a net margin of -2973.05% compared to Kymera Therapeutics, Inc.'s net margin of -15814.98%. Kymera Therapeutics, Inc.'s return on equity of -33.29% beat Cytokinetics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KYMRKymera Therapeutics, Inc.22.25% -$0.94 $1B CYTKCytokinetics, Inc.-38.38% -$2.55 $675.7M -
What do Analysts Say About KYMR or CYTK?
Kymera Therapeutics, Inc. has a consensus price target of $77.59, signalling upside risk potential of 16.47%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $79.56 which suggests that it could grow by 21.14%. Given that Cytokinetics, Inc. has higher upside potential than Kymera Therapeutics, Inc., analysts believe Cytokinetics, Inc. is more attractive than Kymera Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KYMRKymera Therapeutics, Inc.18 0 0 CYTKCytokinetics, Inc.9 4 0 -
Is KYMR or CYTK More Risky?
Kymera Therapeutics, Inc. has a beta of 2.281, which suggesting that the stock is 128.135% more volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.584, suggesting its less volatile than the S&P 500 by 41.614%.
-
Which is a Better Dividend Stock KYMR or CYTK?
Kymera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KYMR or CYTK?
Kymera Therapeutics, Inc. quarterly revenues are $2.8M, which are larger than Cytokinetics, Inc. quarterly revenues of $1.9M. Kymera Therapeutics, Inc.'s net income of -$82.2M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Kymera Therapeutics, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics, Inc. is 124.87x versus 89.61x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KYMRKymera Therapeutics, Inc.124.87x -- $2.8M -$82.2M CYTKCytokinetics, Inc.89.61x -- $1.9M -$306.2M
-
Which has Higher Returns KYMR or GILD?
Gilead Sciences, Inc. has a net margin of -2973.05% compared to Kymera Therapeutics, Inc.'s net margin of 39.21%. Kymera Therapeutics, Inc.'s return on equity of -33.29% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital KYMRKymera Therapeutics, Inc.22.25% -$0.94 $1B GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About KYMR or GILD?
Kymera Therapeutics, Inc. has a consensus price target of $77.59, signalling upside risk potential of 16.47%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 7.77%. Given that Kymera Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Kymera Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KYMRKymera Therapeutics, Inc.18 0 0 GILDGilead Sciences, Inc.16 8 0 -
Is KYMR or GILD More Risky?
Kymera Therapeutics, Inc. has a beta of 2.281, which suggesting that the stock is 128.135% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock KYMR or GILD?
Kymera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.59% to investors and pays a quarterly dividend of $0.79 per share. Kymera Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios KYMR or GILD?
Kymera Therapeutics, Inc. quarterly revenues are $2.8M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Kymera Therapeutics, Inc.'s net income of -$82.2M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Kymera Therapeutics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics, Inc. is 124.87x versus 5.24x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KYMRKymera Therapeutics, Inc.124.87x -- $2.8M -$82.2M GILDGilead Sciences, Inc.5.24x 18.78x $7.8B $3.1B
-
Which has Higher Returns KYMR or PTGX?
Protagonist Therapeutics, Inc. has a net margin of -2973.05% compared to Kymera Therapeutics, Inc.'s net margin of -834.87%. Kymera Therapeutics, Inc.'s return on equity of -33.29% beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.
Company Gross Margin Earnings Per Share Invested Capital KYMRKymera Therapeutics, Inc.22.25% -$0.94 $1B PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M -
What do Analysts Say About KYMR or PTGX?
Kymera Therapeutics, Inc. has a consensus price target of $77.59, signalling upside risk potential of 16.47%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $91.42 which suggests that it could grow by 1.16%. Given that Kymera Therapeutics, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Kymera Therapeutics, Inc. is more attractive than Protagonist Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KYMRKymera Therapeutics, Inc.18 0 0 PTGXProtagonist Therapeutics, Inc.8 1 0 -
Is KYMR or PTGX More Risky?
Kymera Therapeutics, Inc. has a beta of 2.281, which suggesting that the stock is 128.135% more volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.192, suggesting its more volatile than the S&P 500 by 119.221%.
-
Which is a Better Dividend Stock KYMR or PTGX?
Kymera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics, Inc. pays -- of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KYMR or PTGX?
Kymera Therapeutics, Inc. quarterly revenues are $2.8M, which are smaller than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. Kymera Therapeutics, Inc.'s net income of -$82.2M is lower than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, Kymera Therapeutics, Inc.'s price-to-earnings ratio is -- while Protagonist Therapeutics, Inc.'s PE ratio is 141.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics, Inc. is 124.87x versus 27.49x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KYMRKymera Therapeutics, Inc.124.87x -- $2.8M -$82.2M PTGXProtagonist Therapeutics, Inc.27.49x 141.56x $4.7M -$39.3M
-
Which has Higher Returns KYMR or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -2973.05% compared to Kymera Therapeutics, Inc.'s net margin of 38.89%. Kymera Therapeutics, Inc.'s return on equity of -33.29% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital KYMRKymera Therapeutics, Inc.22.25% -$0.94 $1B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About KYMR or REGN?
Kymera Therapeutics, Inc. has a consensus price target of $77.59, signalling upside risk potential of 16.47%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.74%. Given that Kymera Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Kymera Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KYMRKymera Therapeutics, Inc.18 0 0 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is KYMR or REGN More Risky?
Kymera Therapeutics, Inc. has a beta of 2.281, which suggesting that the stock is 128.135% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock KYMR or REGN?
Kymera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Kymera Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KYMR or REGN?
Kymera Therapeutics, Inc. quarterly revenues are $2.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Kymera Therapeutics, Inc.'s net income of -$82.2M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Kymera Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics, Inc. is 124.87x versus 5.56x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KYMRKymera Therapeutics, Inc.124.87x -- $2.8M -$82.2M REGNRegeneron Pharmaceuticals, Inc.5.56x 17.20x $3.8B $1.5B
-
Which has Higher Returns KYMR or TGTX?
TG Therapeutics, Inc. has a net margin of -2973.05% compared to Kymera Therapeutics, Inc.'s net margin of 19.97%. Kymera Therapeutics, Inc.'s return on equity of -33.29% beat TG Therapeutics, Inc.'s return on equity of 145.71%.
Company Gross Margin Earnings Per Share Invested Capital KYMRKymera Therapeutics, Inc.22.25% -$0.94 $1B TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M -
What do Analysts Say About KYMR or TGTX?
Kymera Therapeutics, Inc. has a consensus price target of $77.59, signalling upside risk potential of 16.47%. On the other hand TG Therapeutics, Inc. has an analysts' consensus of $44.29 which suggests that it could grow by 43.97%. Given that TG Therapeutics, Inc. has higher upside potential than Kymera Therapeutics, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Kymera Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KYMRKymera Therapeutics, Inc.18 0 0 TGTXTG Therapeutics, Inc.5 1 0 -
Is KYMR or TGTX More Risky?
Kymera Therapeutics, Inc. has a beta of 2.281, which suggesting that the stock is 128.135% more volatile than S&P 500. In comparison TG Therapeutics, Inc. has a beta of 2.014, suggesting its more volatile than the S&P 500 by 101.386%.
-
Which is a Better Dividend Stock KYMR or TGTX?
Kymera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics, Inc. pays -- of its earnings as a dividend. TG Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KYMR or TGTX?
Kymera Therapeutics, Inc. quarterly revenues are $2.8M, which are smaller than TG Therapeutics, Inc. quarterly revenues of $161.7M. Kymera Therapeutics, Inc.'s net income of -$82.2M is lower than TG Therapeutics, Inc.'s net income of $390.9M. Notably, Kymera Therapeutics, Inc.'s price-to-earnings ratio is -- while TG Therapeutics, Inc.'s PE ratio is 11.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics, Inc. is 124.87x versus 9.35x for TG Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KYMRKymera Therapeutics, Inc.124.87x -- $2.8M -$82.2M TGTXTG Therapeutics, Inc.9.35x 11.07x $161.7M $390.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
